Kelly Lindenboom, Vice President of Corporate Communications, Verenium Corporation

Ms. Lindenboom has more than 15 years of healthcare, life sciences investor and corporate communications experience. Before joining Verenium, she worked for Biosector 2 (B2) a biotechnology communications agency in New York where she provided senior counsel to life sciences companies in the areas of corporate and product communications, issues and crisis management, corporate branding, and investor relations.

Prior to B2, she led the corporate and investor communications group at Ariad Pharmaceuticals, a biotechnology company focused on the development of novel cancer therapies. Before that, Ms. Lindenboom was responsible for product communications at Millennium Pharmaceuticals where she led award-winning communications activities for VELCADE, the Company’s first commercial oncology product. She worked in the New York office of Edelman Public Relations for their healthcare practice and began her communications career as Director of Communications at the American Cancer Society. Ms. Lindenboom studied Literature and Communications at Pace University in Pleasantville, New York. She lives in Del Mar, CA.

Read Kelly Lindenboom’s latest contributions to The Age of Personalized Medicine Blog